AOD-9604 vs Tirzepatide
Side-by-side comparison of AOD-9604 and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
AOD-9604
Tirzepatide
AOD-9604
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence:…
Lowest listed price: $34.99 across 5 listings
Full AOD-9604 profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Category | Metabolic & Weight Loss | Metabolic & Weight Loss |
| Research Stage | Phase 2 (discontinued for obesity); research-use-only | FDA Approved |
| Mechanism of Action | AOD-9604's claimed mechanism is lipolysis (fat breakdown) via a C-terminal hGH-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the mechanistic details remain incompletely characterized and contested. The "Lipolytic… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~30–60 minutes | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 250–600 mcg per injection | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once daily, typically morning fasted | Once weekly subcutaneous injection |
| Administration | Subcutaneous, Oral | Subcutaneous (weekly) |
| Side Effects | AOD-9604's side effect profile is largely benign based on available data, reflecting its failure to produce significant physiological effects - a compound that does little tends to cause few side effects. From the developer's human trials (sponsor-reported; no… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 1817.1 Da | 4813.5 Da |
| Common Vial Sizes | 2mg, 5mg | 5mg, 10mg, 15mg |
Price History
4 data points- BM
- Half Nattys
- Ion Peptide
- Disguised Alpha
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
AOD-9604: potential benefits
- Claimed lipolysis / fat loss (demonstrated only in rodent studies; not shown in human trials)
- Does not raise IGF-1 or activate the GH receptor (no growth or proliferative signaling)
- Does not impair insulin sensitivity or glucose tolerance in studies to date
- Benign short-term safety and tolerability profile
- Cartilage-protective effect in an animal (rabbit) osteoarthritis model - preclinical only
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between AOD-9604 and Tirzepatide?
AOD-9604 is a metabolic & weight loss that aod-9604's claimed mechanism is lipolysis (fat breakdown) via a c-terminal hgh-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~30–60 minutes vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, AOD-9604 or Tirzepatide?
AOD-9604 has a half-life of ~30–60 minutes. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, AOD-9604 or Tirzepatide?
Lowest listed price on BodyHackGuide: AOD-9604 from $34.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack AOD-9604 and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. AOD-9604 and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy AOD-9604 or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.